In vivo bio luminescence imaging of burkholderia mallei respiratory infection and treatment in the mouse model

Shane Massey, Katie Johnston, Tiffany M. Mott, Barbara M. Judy, Brian H. Kvitko, Herbert P. Schweizer, D. Mark Estes, Alfredo Torres

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Bioluminescent imaging (BLI) technology is a powerful tool for monitoring infectious disease progression and treatment approaches. BLI is particularly useful for tracking fastidious intracellular pathogens that might be difficult to recover from certain organs. Burkholderia mallei, the causative agent of glanders, is a facultative intracellular pathogen and has been classified by the CDC as a Category B select agent due to its highly infectious nature and potential use as a biological weapon. Very little is known regarding pathogenesis or treatment of glanders. We investigated the use of bioluminescent reporter constructs to monitor the dynamics of infection as well as the efficacy of therapeutics for B. mallei in real-time. A stable luminescent reporter B. mallei strain was created using the pUTmini-Tn5 luxKm2 plasmid and used to monitor glanders in the BALB/c murine model. Mice were infected via the intranasal route with 5 × 103 bacteria and monitored by BLI at 24, 48, and 72 h. We verified that our reporter construct maintained similar virulence and growth kinetics compared to wild-type B. mallei and confirmed that it maintains luminescent stability in the presence or absence of antibiotic selection. The luminescent signal was initially seen in the lungs, and progressed to the liver and spleen over the course of infection. We demonstrated that antibiotic treatment 24 h post-infection resulted in reduction of bioluminescence that can be attributed to decreased bacterial burden in target organs. These findings suggest that BLI can be used to monitor disease progression and efficacy of therapeutics during glanders infections. Finally, we report an alternative method to mini-Tn5::luxKm2 transposon using mini-Tn7-lux elements that insert site-specifically at known genomic attachment sites and that can also be used to tag bacteria.

Original languageEnglish (US)
Article numberArticle 174
JournalFrontiers in Microbiology
Volume2
Issue numberAUG
DOIs
StatePublished - 2011

Fingerprint

Burkholderia mallei
Glanders
Luminescence
Respiratory Tract Infections
Infection
Disease Progression
Biological Warfare Agents
Anti-Bacterial Agents
Bacteria
Centers for Disease Control and Prevention (U.S.)
Communicable Diseases
Virulence
Plasmids
Spleen
Technology
Lung
Liver
Therapeutics
Growth

Keywords

  • Antibiotic
  • Bioluminescence
  • Burkholderia mallei
  • In vivo imaging

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

In vivo bio luminescence imaging of burkholderia mallei respiratory infection and treatment in the mouse model. / Massey, Shane; Johnston, Katie; Mott, Tiffany M.; Judy, Barbara M.; Kvitko, Brian H.; Schweizer, Herbert P.; Estes, D. Mark; Torres, Alfredo.

In: Frontiers in Microbiology, Vol. 2, No. AUG, Article 174, 2011.

Research output: Contribution to journalArticle

Massey, Shane ; Johnston, Katie ; Mott, Tiffany M. ; Judy, Barbara M. ; Kvitko, Brian H. ; Schweizer, Herbert P. ; Estes, D. Mark ; Torres, Alfredo. / In vivo bio luminescence imaging of burkholderia mallei respiratory infection and treatment in the mouse model. In: Frontiers in Microbiology. 2011 ; Vol. 2, No. AUG.
@article{c9a93b5a2b42416dba7cfe1ddfb2821f,
title = "In vivo bio luminescence imaging of burkholderia mallei respiratory infection and treatment in the mouse model",
abstract = "Bioluminescent imaging (BLI) technology is a powerful tool for monitoring infectious disease progression and treatment approaches. BLI is particularly useful for tracking fastidious intracellular pathogens that might be difficult to recover from certain organs. Burkholderia mallei, the causative agent of glanders, is a facultative intracellular pathogen and has been classified by the CDC as a Category B select agent due to its highly infectious nature and potential use as a biological weapon. Very little is known regarding pathogenesis or treatment of glanders. We investigated the use of bioluminescent reporter constructs to monitor the dynamics of infection as well as the efficacy of therapeutics for B. mallei in real-time. A stable luminescent reporter B. mallei strain was created using the pUTmini-Tn5 luxKm2 plasmid and used to monitor glanders in the BALB/c murine model. Mice were infected via the intranasal route with 5 × 103 bacteria and monitored by BLI at 24, 48, and 72 h. We verified that our reporter construct maintained similar virulence and growth kinetics compared to wild-type B. mallei and confirmed that it maintains luminescent stability in the presence or absence of antibiotic selection. The luminescent signal was initially seen in the lungs, and progressed to the liver and spleen over the course of infection. We demonstrated that antibiotic treatment 24 h post-infection resulted in reduction of bioluminescence that can be attributed to decreased bacterial burden in target organs. These findings suggest that BLI can be used to monitor disease progression and efficacy of therapeutics during glanders infections. Finally, we report an alternative method to mini-Tn5::luxKm2 transposon using mini-Tn7-lux elements that insert site-specifically at known genomic attachment sites and that can also be used to tag bacteria.",
keywords = "Antibiotic, Bioluminescence, Burkholderia mallei, In vivo imaging",
author = "Shane Massey and Katie Johnston and Mott, {Tiffany M.} and Judy, {Barbara M.} and Kvitko, {Brian H.} and Schweizer, {Herbert P.} and Estes, {D. Mark} and Alfredo Torres",
year = "2011",
doi = "10.3389/fmicb.2011.00174",
language = "English (US)",
volume = "2",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - In vivo bio luminescence imaging of burkholderia mallei respiratory infection and treatment in the mouse model

AU - Massey, Shane

AU - Johnston, Katie

AU - Mott, Tiffany M.

AU - Judy, Barbara M.

AU - Kvitko, Brian H.

AU - Schweizer, Herbert P.

AU - Estes, D. Mark

AU - Torres, Alfredo

PY - 2011

Y1 - 2011

N2 - Bioluminescent imaging (BLI) technology is a powerful tool for monitoring infectious disease progression and treatment approaches. BLI is particularly useful for tracking fastidious intracellular pathogens that might be difficult to recover from certain organs. Burkholderia mallei, the causative agent of glanders, is a facultative intracellular pathogen and has been classified by the CDC as a Category B select agent due to its highly infectious nature and potential use as a biological weapon. Very little is known regarding pathogenesis or treatment of glanders. We investigated the use of bioluminescent reporter constructs to monitor the dynamics of infection as well as the efficacy of therapeutics for B. mallei in real-time. A stable luminescent reporter B. mallei strain was created using the pUTmini-Tn5 luxKm2 plasmid and used to monitor glanders in the BALB/c murine model. Mice were infected via the intranasal route with 5 × 103 bacteria and monitored by BLI at 24, 48, and 72 h. We verified that our reporter construct maintained similar virulence and growth kinetics compared to wild-type B. mallei and confirmed that it maintains luminescent stability in the presence or absence of antibiotic selection. The luminescent signal was initially seen in the lungs, and progressed to the liver and spleen over the course of infection. We demonstrated that antibiotic treatment 24 h post-infection resulted in reduction of bioluminescence that can be attributed to decreased bacterial burden in target organs. These findings suggest that BLI can be used to monitor disease progression and efficacy of therapeutics during glanders infections. Finally, we report an alternative method to mini-Tn5::luxKm2 transposon using mini-Tn7-lux elements that insert site-specifically at known genomic attachment sites and that can also be used to tag bacteria.

AB - Bioluminescent imaging (BLI) technology is a powerful tool for monitoring infectious disease progression and treatment approaches. BLI is particularly useful for tracking fastidious intracellular pathogens that might be difficult to recover from certain organs. Burkholderia mallei, the causative agent of glanders, is a facultative intracellular pathogen and has been classified by the CDC as a Category B select agent due to its highly infectious nature and potential use as a biological weapon. Very little is known regarding pathogenesis or treatment of glanders. We investigated the use of bioluminescent reporter constructs to monitor the dynamics of infection as well as the efficacy of therapeutics for B. mallei in real-time. A stable luminescent reporter B. mallei strain was created using the pUTmini-Tn5 luxKm2 plasmid and used to monitor glanders in the BALB/c murine model. Mice were infected via the intranasal route with 5 × 103 bacteria and monitored by BLI at 24, 48, and 72 h. We verified that our reporter construct maintained similar virulence and growth kinetics compared to wild-type B. mallei and confirmed that it maintains luminescent stability in the presence or absence of antibiotic selection. The luminescent signal was initially seen in the lungs, and progressed to the liver and spleen over the course of infection. We demonstrated that antibiotic treatment 24 h post-infection resulted in reduction of bioluminescence that can be attributed to decreased bacterial burden in target organs. These findings suggest that BLI can be used to monitor disease progression and efficacy of therapeutics during glanders infections. Finally, we report an alternative method to mini-Tn5::luxKm2 transposon using mini-Tn7-lux elements that insert site-specifically at known genomic attachment sites and that can also be used to tag bacteria.

KW - Antibiotic

KW - Bioluminescence

KW - Burkholderia mallei

KW - In vivo imaging

UR - http://www.scopus.com/inward/record.url?scp=84866069005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866069005&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2011.00174

DO - 10.3389/fmicb.2011.00174

M3 - Article

VL - 2

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - AUG

M1 - Article 174

ER -